Authors
Panagiotis A Konstantinopoulos, Steven Waggoner, Gregory A Vidal, Monica Mita, John W Moroney, Robert Holloway, Linda Van Le, Jasgit C Sachdev, Eloise Chapman-Davis, Gerardo Colon-Otero, Richard T Penson, Ursula A Matulonis, Young Bae Kim, Kathleen N Moore, Elizabeth M Swisher, Anniina Färkkilä, Alan D’Andrea, Erica Stringer-Reasor, Jing Wang, Nathan Buerstatte, Sujata Arora, Julie R Graham, Dmitri Bobilev, Bruce J Dezube, Pamela Munster
Publication date
2019/8/1
Journal
JAMA oncology
Volume
5
Issue
8
Pages
1141-1149
Publisher
American Medical Association
Description
Importance
Patients with recurrent ovarian carcinoma frequently develop resistance to platinum-based chemotherapy, at which time treatment options become limited.
Objective
To evaluate the poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitor niraparib combined with pembrolizumab in patients with recurrent ovarian carcinoma.
Design, Setting, and Participants
The TOPACIO/KEYNOTE-162 (Niraparib in Combination With Pembrolizumab in Patients With Triple-Negative Breast Cancer or Ovarian Cancer) trial, an open-label, single-arm phases 1 and 2 study enrolled women with advanced or metastatic triple-negative breast cancer (TNBC) or recurrent ovarian carcinoma, irrespective ofBRCAmutation status. Median follow-up was 12.4 months (range, 1.2 to ≥23.0 months). Data were collected from April 15, 2016, through September 4, 2018, with September 4, 2018, as a data cutoff, and analyzed from …
Scholar articles
PA Konstantinopoulos, S Waggoner, GA Vidal, M Mita… - JAMA oncology, 2019